Lie Li

发表

Evaluation of artemisinins for the treatment of acute myeloid leukemia

A. Shelat, R. Guy, C. Drenberg, 2016, Cancer Chemotherapy and Pharmacology.

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.

S. Baker, M. Rudek, K. Pratz, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)

M. Absalon, S. Baker, E. Sison, 2017, Pediatric blood & cancer.

Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice

M. Relling, S. Karol, Xiangjun Cai, 2020, Haematologica.

A phosphotyrosine switch regulates organic cation transporters

E. Isacoff, A. Sali, S. Ong, 2016, Nature Communications.

Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy.

U. Hofmann, T. Morio, Motohiro Kato, 2018, Blood.

Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies

Sara M. Federico, S. Shurtleff, C. Pui, 2019, Clinical Cancer Research.

Alternative formulations of sorafenib for use in children

S. Baker, Xiangjun Cai, F. Navid, 2013, Pediatric blood & cancer.

Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia

S. Shurtleff, D. Finkelstein, C. Drenberg, 2017, The Journal of clinical investigation.

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

J. Panetta, S. Baker, A. Gibson, 2015, Cancer research.

Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53

A. Gibson, A. Sparreboom, E. Schlatter, 2014, Clinical Cancer Research.

Cancer Therapy : Preclinical Cisplatin-Induced Renal Injury Is Independently Mediated by OCT 2 and p 53

A. Gibson, A. Sparreboom, E. Schlatter, 2014 .

OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.

C. Drenberg, S. Baker, A. Gibson, 2017, Cancer research.

NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity

U. Hofmann, M. Relling, C. Pui, 2016, Nature Genetics.

Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions

S. Ong, Taosheng Chen, A. Gibson, 2015, Proceedings of the National Academy of Sciences.

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

S. Shurtleff, D. Campana, C. Pui, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.

Taosheng Chen, Junmin Peng, Jing Ma, 2015, Cancer cell.

Dasatinib does not exacerbate dexamethasone‐induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy

M. Relling, S. Karol, K. Crews, 2021, Pediatric blood & cancer.

Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity

Kenneth A. Matreyek, M. Relling, D. Fowler, 2020, Proceedings of the National Academy of Sciences.

Ontogeny and Sorafenib Metabolism

D. Finkelstein, E. Schuetz, S. Baker, 2012, Clinical Cancer Research.

Cancer Therapy : Clinical Ontogeny and Sorafenib Metabolism

D. Finkelstein, E. Schuetz, S. Baker, 2012 .

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

S. Baker, A. Gibson, A. Sparreboom, 2013, Clinical Cancer Research.

Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase Ⅲ trial

Min Zhang, Lie Li, Zhigang Cheng, 2022, Frontiers in Pharmacology.

L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model

M. Relling, Yiwei Liu, L. Janke, 2019, Leukemia & lymphoma.

Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia

C. Pui, D. Teachey, C. Mullighan, 2023, Leukemia.

Identification of small molecules that mitigate vincristine‐induced neurotoxicity while sensitizing leukemia cells to vincristine

M. Relling, Cheng Cheng, C. Pui, 2021, Clinical and translational science.

Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib

S. Baker, A. Gibson, R. Williams, 2013, Clinical Cancer Research.

Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance

A. Gibson, A. Sparreboom, Shuiying Hu, 2013, Clinical pharmacology and therapeutics.

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity

D. Finkelstein, S. Baker, A. Gibson, 2017, Clinical and translational science.

OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.

C. Drenberg, S. Baker, A. Gibson, 2017, Cancer research.

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

S. Shurtleff, D. Campana, C. Pui, 2010 .

Contribution of Oatp1b1 and Oatp1b3 to the Disposition of Sorafenib and Sorafenib- Glucuronide Total Number of Figures and Tables: 5

A. Gibson, A. Sparreboom, Shuiying Hu, 2022 .